

Food sources of fructose-containing sugars and glycemic control: A systematic review and meta-analysis of controlled intervention studies in people with and without diabetes

Vivian L Choo^{1,2}, Effie Vigiou^{1,2}, Sonia Blanco Mejia^{1,2}, Adrian I Cozma^{1,2}, Tauseef A Khan^{1,2}, Vanessa Ha^{1,3}, Thomas MS Wolever^{1,2,4,5}, Lawrence A Leiter^{1,4,5}, Vladimir Vuksan^{1,2,4}, Cyril WC Kendall^{1,2,6}, Russell J de Souza^{1,3}, David JA Jenkins^{1,2,4,5} and John L Sievenpiper^{1,2,4}

¹Toronto 3D (Diet, Digestive Tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, ON, Canada; ²Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; ³Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada and ⁴Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; ⁵Division of Endocrinology, St. Michael's Hospital, Toronto, ON, Canada; ⁶College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada

Keywords: Fructose, HFCS, sucrose, glycemic control, diabetes, meta-analysis

Corresponding Author:

John L Sievenpiper MD, PhD, FRCPC

Toronto 3D Knowledge Synthesis and Clinical Trials Unit

Clinical Nutrition and Risk Factor Modification Centre,

St. Michael's Hospital

61 Queen Street East, Toronto, ON, M5C 2T2, CANADA

Tel: 416 867 7475

Fax: 416 867 7495

Email: john.sievenpiper@medportal.ca

Abstract Word Count: 400

Text Word Count: 6972

Tables: 2

Figures: 4

Supplementary Tables: 3

Supplementary Figures: 27

WHAT THIS PAPER ADDS

What is already known on this topic

Current dietary guidelines recommend a reduction to <5-10% energy in free sugars, especially fructose-containing sugars from sugars-sweetened beverages (SSBs).

Fructose-containing sugars from SSBs have shown an adverse association with diabetes incidence in systematic reviews and meta-analyses of prospective cohort studies and free fructose adding excess energy to diets has shown a harmful effect on glycemic control in systematic reviews and meta-analyses of controlled intervention studies.

As dietary guidelines shift from a focus on single nutrients to a focus on dietary patterns, it is unclear whether the evidence for SSBs and excess energy from fructose holds for other important food sources of fructose-containing sugars at different levels of energy control.

What this study adds

Our systematic review and meta-analysis of 155 controlled intervention studies suggests that most food sources of fructose-containing sugars do not have a harmful effect on glycemic control in energy-matched substitutions for other macronutrients but several food sources do have harmful effects when adding excess energy to the diet, especially SSBs.

While awaiting further research, public health professionals should be aware that harmful effects of fructose-containing sugars on glycemic control appear to be mediated by energy and food source.

ABSTRACT

Objective: As dietary guidelines move to dietary pattern-based recommendations, it is unclear whether the evidence supporting current recommendations to reduce free sugars, especially those from sugar-sweetened beverages (SSBs), holds for all food sources. Our objective was to assess the effect of different food sources of fructose-containing sugars on glycemic control at different levels of energy control.

Design: Systematic review and meta-analysis of controlled intervention studies

Data Sources: MEDLINE, EMBASE, and The Cochrane library through April 25, 2018.

Eligibility criteria for selecting studies: We included controlled intervention studies of ≥ 7 -days assessing the effect of different food sources of fructose-containing sugars on glycemic control in people with and without diabetes. We prespecified 4 study designs based on energy control: substitution studies (sugars in energy matched comparisons with other macronutrients); addition studies (excess energy from sugars added to diets); subtraction studies (energy from sugars subtracted from diets); and ad libitum studies (sugars freely replaced by other macronutrients without control for energy). Outcomes were HbA1c, fasting blood glucose, and fasting blood glucose insulin.

Data extraction and synthesis: Four independent reviewers extracted relevant data and assessed risk of bias. Data were pooled using random effects models and expressed as mean differences with 95% confidence intervals (95% CIs). The overall certainty of the evidence was assessed using GRADE.

Results: We included 155 study comparisons (N=5,086). Whereas total fructose containing sugars had no harmful effect on any outcome in substitution or subtraction studies with a decrease seen in HbA1c (mean difference, -0.22% [95% CI to -0.35, -0.08%], -25.9mmol/mol [-27.3 to -24.4mmol/mol]) in substitution studies, there was a harmful effect on fasting insulin in addition (4.68pmol/L [1.40 to 7.96]) and ad libitum (7.24pmol/L [0.47 to 14.00]) studies. There was interaction by food source with specific food sources showing beneficial-effects (fruit and fruit juice) or harmful-effects (sweetened-milk and mixed sources) in substitution studies and harmful-effects (SSBs and fruit juice) in addition studies on at least one outcome. The majority of the evidence was low quality.

Conclusions: Energy control and food source appear to mediate the effect of fructose-containing sugars on glycemic control. Whereas most food sources of fructose-containing sugars (especially fruit) do not have a harmful effect in energy-matched substitutions with other macronutrients, several food sources of fructose-containing sugars (especially SSBs) adding excess energy to diets do have harmful effects. Our certainty in these estimates is low. More high-quality randomized controlled trials are needed.

Registration: ClinicalStudies.gov identifier, NCT02716870.

INTRODUCTION

The role of sugars in the development of cardiometabolic disease is actively debated (1, 2). In particular, fructose has recently emerged as a serious public health concern, as ecological parallels have been drawn between the introduction of high fructose corn syrup (HFCS) as a popular sweetener during the 1970s and global rises in obesity and diabetes prevalence (3, 4).

Despite early considerations for the use of fructose as an alternative sweetener in people with diabetes due to its observed potential to lower postprandial glycemic excursions when compared to isocaloric amounts of starch (5), a mounting body of evidence has suggested that fructose may be particularly detrimental to metabolic health, even more so than other sugars (6). This view has received support from ecological evidence(4) as well as animal (7-9) and select human intervention studies(10-12). However, higher levels of evidence from systematic reviews and meta-analyses of controlled human intervention studies have failed to demonstrate adverse glycemic effects unique to fructose, and have even shown a beneficial effect on glycated blood proteins of fructose in isocaloric substitution for other carbohydrates in the diet in people with diabetes (13).

Whether there exists a causal link between fructose and the development of diabetes and related cardiometabolic co-morbidities continues to be contested, though much less appreciated in this debate are the consumption patterns and levels at which fructose is normally consumed in the diet. Fructose is rarely consumed in isolation under real world conditions (14). It is present in a variety of food sources containing comparable amounts of glucose, and the proportion of fructose co-ingested with glucose has been suggested to influence fructose metabolism (15). In its most commonly consumed form, sucrose (table sugar), fructose is part of a disaccharide with glucose in a 50:50 ratio. HFCS is also a glucose-fructose mix, with varying fructose content (42-55% molecular weight) in a free, unbound monosaccharide form. Similarly, less refined sources of fructose-containing sugars, including honey, agave and maple syrup, are composed of varying proportions of fructose and glucose, while natural sources of fructose present in various fruit and

vegetables also co-exist with glucose. These fructose-containing sugars are found in the diet in a variety of food sources, ranging from “nutrient poor” sources of added sugars such as sugars-sweetened beverages (SSBs), to “nutrient dense” sources of bound sugars such as fruit. Evidence from prospective cohorts on diabetes risk have shown differential associations depending on the food source of the sugars (positive associations with SSBs (16, 17) and inverse association with fruit (18, 19)).

As dietary guidelines shift from nutrient-based recommendations to more food and dietary pattern-based recommendations (20, 21), it is important to understand the role of the food matrix in modifying the effect of fructose-containing sugars. Current recommendations from the WHO, U.S., and England have focussed on the reduction of added or free sugars (added sugars plus sugars contained in fruit juices) to <5-10% energy (20, 22, 23), especially free fructose-containing sugars from sugars-sweetened beverages (SSBs) (20). Whether the evidence for added or free sugars and SSBs can be generalized to all food sources of fructose-containing sugars in relation to their effects on surrogate markers of type 2 diabetes has not yet been determined. We conducted a systematic review and meta-analysis of controlled intervention studies to determine the effect of food sources of fructose-containing sugars at different levels of energy control on glycemic control in people with and without diabetes.

METHODS

This systematic review and meta-analysis was conducted according to the Cochrane Handbook for Systematic Reviews and interventions(24), with all results reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (25). The study protocol was registered at ClinicalStudies.gov, (identification number, NCT02716870).

Data Sources

Medline, EMBASE and the Cochrane Central Register of Controlled Studies were searched through April 25, 2018 using the following search terms: fructose OR dietary sucrose, OR HFCS OR sugar OR sugar* sweetened beverage* OR honey AND glyc?em* OR insulin OR HbA1c OR fructosamine OR blood glucose OR gly* albumin (Supplementary Table 1). Validated filters from McMaster University Health Information Research Unit were applied to limit the database search to controlled studies only (26), and electronic searches were supplemented with manual searches of references from included studies.

Study Selection

We included reports of controlled intervention studies lasting ≥ 7 days investigating the effect of diets of fructose-containing sugars (fructose, sucrose, HFCS, honey, syrups) from various food sources compared with control diets free of or lower in fructose-containing sugars on outcome measures of glycemic control (fasting glucose, fasting insulin, and HbA1c) in people with and without diabetes. We excluded reports of studies of meal replacements and studies of interventions of rare sugars that contained fructose (e.g. isomaltulose or melzitose) or were low-calorie epimers of fructose (e.g. allulose, tagatose, sorbose) or studies that used these sugars as the comparator. Four study designs based on the control of energy were prespecified: 1) 'substitution' studies, in which food sources of

fructose-containing sugars were compared with food sources of other non-fructose-containing macronutrients under energy matched conditions (isocaloric comparison); (2) 'addition' studies, in which excess energy from food sources of fructose-containing sugars was added to background diets compared to the same background diets alone without the excess energy from fructose-containing sugars with or without the use of low-calorie sweeteners to match sweetness (hypercaloric comparison); (3) 'subtraction' studies, in which energy from food sources of fructose-containing sugars was subtracted from background diets through displacement by water and/or low-calorie sweeteners, or by eliminating the food sources of fructose-containing sugars altogether compared with the original background diets (hypocaloric comparison); and (4) 'ad libitum' studies, in which food sources of fructose-containing sugars were compared with food sources of other non-fructose-containing macronutrients without any strict control of either the study foods or the background diets to allow for free replacement of the energy from fructose-containing sugars with the energy from other macronutrients (free-feeding comparison). Reports containing both randomized and non-randomized controlled intervention studies were included. An intervention study was considered non-randomized if the authors explicitly stated that a method of randomization was not used or randomization was not reported in the allocation of participants to the intervention or control treatments in parallel designs or the sequence of the treatments in crossover designs. In reports containing more than one study comparison, we included all available study comparisons.

Patient and Public Involvement

No patient/public was involved in the design, writing or editing of this study.

Data Extraction

Data from included reports were individually extracted at least twice by four separate reviewers. Relevant information included number of participants, setting, underlying disease status of participants, study design, level of feeding control, randomization, comparator, fructose-containing sugars type, food sources of fructose-containing sugars, macronutrient profile of the diets, follow-up duration, energy balance, and funding sources. The three outcome variables were HbA1c, fasting blood glucose, and fasting blood insulin. HbA1c was reported instead of total glycated blood proteins as originally indicated in our protocol (identification number, NCT02716870), as mean differences for these values were considered more clinically relevant and did not require the use of standardized mean differences needed to the different glycated blood proteins. Authors were contacted for missing outcome data when it was indicated that an outcome was measured but not reported. In the absence of numerical values for outcome measurements and inability to obtain the original data from authors, values were extracted from figures using Plot Digitizer where available(1). All discrepancies between reviewers were resolved through consensus or, where necessary, arbitration by the senior author.

Study quality

Included studies were assessed for risk of bias by at least 2 of the reviewers using the Cochrane Collaboration Risk of bias Tool(27). Final assessments were based on consensus between reviewers.

Data Synthesis and Analysis

We used Review Manager (RevMan) version 5.2 (Copenhagen, Denmark) for primary analyses and Stata (version 12, College Station, TX, USA) for subgroup, dose response, and publication bias analyses. We performed separate analyses for the 4 prespecified study designs based on the control of energy (substitution, addition, subtraction, and ad libitum studies) and stratified analyses by food sources of sugars for each of three outcome variables (HbA1c, fasting blood glucose, and fasting blood insulin). The principal effect measure was the mean pair-wise difference (MD) in change from baseline (or, when not available, the post-treatment value) between the food sources of fructose-containing sugars arm and the comparator arm with results reported as mean differences (MD) with 95% confidence intervals (CI). We extracted the estimates of the MD and corresponding 95% confidence intervals for each outcome. Change-from-baseline differences were preferred over end differences and paired analyses were applied to all crossover trials with the use of a within-individual correlation coefficient between treatments of 0.5 as described by Elbourne et al.(28). When at least two studies provided data, we performed a DerSimonian and Laird random effects meta-analysis. When less than 5 studies were available for analysis, we also considered fixed effect estimates. Heterogeneity was assessed by the Cochran Q test (significant at $P < 0.10$) and quantified by the I² statistic (range 0%-100%)(29). The interaction of fructose-containing sugars x food source was assessed using the Chi-square statistic. Other sources of heterogeneity were explored using sensitivity and subgroup analyses. We carried out sensitivity analyses by systematically removing each study from the meta-analyses and recalculating the summary association. A study whose removal explained the heterogeneity, changed the significance of the effect, or altered the effect size by 10% or more, was considered an influential study. If ≥ 10 studies per outcome were available (30, 31), then we conducted a priori subgroup and analyses using meta-regression. Categorical subgroup analyses were done for energy balance (positive, neutral, negative), comparator (starch, glucose, fat, lactose, maltodextrin, diet alone, water, non-nutritive sweeteners, protein, mixed sources), fructose-containing sugars type (fruit, sucrose, fructose, HFCS, honey), fructose-containing sugars dose ($\leq 10\%$, $> 10\%$ energy (22, 32)), baseline values for HbA1c ($\leq 7\%$, $> 7\%$), fasting glucose (≤ 5.5 , > 5.5 mmol/L based on median values) and insulin (≤ 96.6 , > 96.6 pmol/L based on median values), age (≤ 18 , > 18), study design (crossover, parallel), follow-up duration (< 8 weeks, ≥ 8 weeks), randomization (yes, no), level of feeding control (supplemented, dietary advice and metabolically controlled), underlying disease status (diabetes, overweight/ obese, metabolic syndrome criteria, otherwise healthy), and individual domains of risk of bias (sequence generation, allocation concealment, blinding of participants/ personnel and outcome assessors, incomplete outcome data, selective outcome reporting). Continuous dose response analyses were performed using meta-regression to assess linear dose-response gradients and non-linear meta-regression (MKSPLINE procedure) with knots at the public health thresholds of 5% (22, 23), 10% (22, 33), and 25% (34) energy to assess non-linear dose-threshold effects. If ≥ 10 studies per outcome were available(35), then we assessed publication bias by inspection of funnel plots and formal testing with the Egger and Begg tests. If there was evidence of publication bias, then we used the Duval and Tweedie trim and fill method to adjust for funnel plot asymmetry by imputing missing study data (36).

Grading of the evidence

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty in our estimates and produce evidence profiles (37) using GRADEpro GDT (GRADEpro Guideline Development Tool [Software], McMaster University, Canada, 2015). Evidence was graded as high, moderate, low or very low quality. Included controlled intervention studies were graded as high quality evidence by default and downgraded based on pre-specified criteria. Criteria to downgrade evidence included risk of bias (assessed through the Cochrane Risk of Bias tool), inconsistency (substantial unexplained heterogeneity, $I^2 > 50\%$, $P < 0.10$), indirectness (presence of factors that limited the generalizability of the results), imprecision (the 95% CI for pooled effect estimates crossed a minimally important difference [MID] for benefit or harm for HbA1c [$\pm 0.3\%$], fasting blood glucose [± 0.5 mmol/L], and fasting blood insulin [± 10 pmol/L]), and publication bias (significant evidence of publication bias).

RESULTS

Search Results

The systematic search and selection of literature is shown in Figure 1. 4,442 reports were identified from database and manual searches, of which 4,157 were excluded based on title and abstract. 285 reports were reviewed in full, of which an additional 164 reports were excluded for failure to meet the eligibility criteria. 118 reports of controlled intervention studies (5, 11, 12, 38-152) including a total of 155 study comparisons in 5,086 participants were included in the final analysis.

Study Characteristics

A summary of the mean study characteristics is presented by the 4 prespecified study designs (substitution, addition, subtraction, and ad libitum studies) in Table 1, with a breakdown of individual study characteristics in Supplementary Table 2. Study sizes were relatively small, ranging from a median of 15 participants (range 6-318) in subtraction studies to 39 (range 8-236) participants in ad libitum studies. The majority of studies were performed in an outpatient setting, with almost half of all substitution (43/108), addition (12/35) and subtraction (1/5) studies conducted in the USA, and all ad libitum studies conducted in European countries. Participants tended to be middle aged, with approximately equal ratios of males to females in substitution, addition and ad libitum studies, but proportionately more females in subtraction studies. Most studies were conducted in those with diabetes (34%, 37/108) or otherwise healthy participants (26%, 28/108) in substitution studies; otherwise healthy (34%, 12/35) or overweight/obese (29%, 10/35) in addition studies; overweight or obese (80%, 4/5) in subtraction studies; and otherwise healthy (43%, 3/7) in ad libitum studies. Most studies were randomized (72% [78/108] of substitution studies, 66% [23/35] of addition studies, 80% [4/5] of subtraction studies and 100% [7/7] of ad libitum studies). Follow up duration was relatively short, ranging from a median of 4.5 weeks (range 1- 52 weeks) in substitution studies to 12 weeks (range 1-36 weeks) in subtraction studies. Fructose-containing sugars doses ranged from a median of 12.2% (range 7.7-25.0%) of total energy intake in addition studies to 23% (range 13.0-26.0%) of total energy intake in ad libitum studies, and were mostly in the form of mixed food sources in substitution (45/108) and ad libitum (6/7) studies while most addition (12/35) and subtraction (4/5) studies used sugars-sweetened beverages. Most studies were funded by agency sources (government, not-for-profit health agency or university sources), except for ad libitum trials which were primarily funded by agency-industry funding.

Study quality

A summary of the risk of bias assessments by the Cochrane Risk of Bias Tool is shown in Supplementary Figure 1. Owing to poor reporting standards, most studies were assessed as having unclear risk of bias across the 5 domains of bias. Few studies were assessed as having high risk of bias with only 20.3% (24/118), 23.7% (28/118), 1.7% (2/118), 8.5% (10/118) of studies assessed as high risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, and incomplete outcome data, respectively. Overall, no serious risk of bias was detected.

Outcomes: HbA1c

The effect of different food sources of fructose-containing sugars on HbA1c are shown in Figure 2 and Supplementary Figures 2-5. Total fructose-containing sugars independent of food sources showed a significant beneficial effect on HbA1c in substitution studies (30 study comparisons, MD=-0.22% [95% CI, -0.35 to -0.08], -25.9mmol/mol [95% CI, -27.3 to -24.4mmol/mol], $p<0.01$, substantial heterogeneity [$I^2=82%$, $p<0.001$]). There was no significant effect in addition (6 study comparisons, substantial heterogeneity [$I^2=83%$, $p<0.001$]), subtraction (1 study comparison) or ad libitum (1 study comparison) studies. Although formal tests of interaction by food source were not significant in the substitution or addition studies, an interaction appeared to be present in the substitution studies, as fruit was the major driver of the effect accounting for 30% of the weighted benefit as the only food source that showed a significant decrease in HbA1c (6 study comparisons, MD=-0.19% [95% CI, -0.35 to -0.03], -25.6mmol/mol [95% CI, -27.3 to -23.8mmol/mol], $p=0.02$, substantial heterogeneity [$I^2=78%$, $p<0.001$]). An interaction by food source could not be assessed at the other levels of energy control, as only one food source category was assessed in the subtraction (SSBs) and ad libitum (baked goods, sweets and desserts) studies.

Sensitivity analyses for HbA1c are presented in Supplementary table 3. The removal of each study did not explain the heterogeneity or change the significance of the effect.

A priori subgroup analyses for HbA1c are presented in supplementary figures 6 and 7 and dose-response analyses for HbA1c are presented in Supplementary Figure 8 and 9. A priori subgroup analyses did not reveal any effect modification in substitution studies. There was evidence of a dose threshold seen at 10% energy by MKSPLINE procedure with the largest decreases seen only at doses $\leq 10%$ energy ($P=0.04$). No subgroup or dose-response analyses were conducted for addition, subtraction or ad libitum studies, as less than 10 studies were available for analyses.

Outcomes: Fasting Blood Glucose

The effect of different food sources of fructose-containing sugars on fasting blood glucose are shown in Figure 3 and Supplementary Figures 10-13. Total fructose-containing sugars independent of food sources had no effect on fasting blood glucose in substitution studies (99 study comparisons, substantial heterogeneity [$I^2=65$, $p<0.001$]), addition studies (28 study comparisons, substantial heterogeneity [$I^2=71$, $p<0.001$]), subtraction studies (4 study comparisons, substantial heterogeneity [$I^2=59$, $p=0.06$]) or ad libitum studies (6 study

comparisons, no evidence of heterogeneity). There was a significant interaction by food source in addition studies ($P < 0.001$): SSBs (11 study comparisons, MD= 0.12 mmol/L [95% CI, 0.03 to 0.22], substantial heterogeneity [$I^2=74$], $p < 0.001$) and fruit juice (2 study comparisons, MD= 0.29 mmol/L [95% CI, 0.09 to 0.49], no evidence of heterogeneity) showed a significant harmful effect, while fruit (7 study comparisons), fruit drinks (3 study comparisons), sweetened chocolate (1 study comparison), added sweeteners (3 study comparisons), and mixed sources (1 study comparison) showed no significant effect on fasting blood glucose. No significant interaction by food source was seen in the substitution, subtraction or ad libitum studies, although only one food source category was assessed in the subtraction studies (SSBs) and ad libitum studies (mixed sources).

Sensitivity analyses for fasting blood glucose are presented in Supplementary Table 3. Removal of anyone of 6 addition studies (38, 46, 72, 105, 114, 123) changed the significance from non-significant to significant but did not change the magnitude or direction of the effect or the evidence of substantial heterogeneity. Removal of the subtraction study by Campos et al. 2015 (group 2 [G2]) (60) explained all of the heterogeneity, changing the direction but not the lack of significance of the effect on fasting blood glucose. Finally, removal of the subtraction study by Tate et al. 2012 (148) explained most of the heterogeneity ($I^2=32\%$, $P=0.23$) but did not change the direction or lack of significance of the effect on fasting blood glucose.

A priori subgroup analyses for fasting blood glucose are presented in Supplementary Figures 14-17 and dose-response analyses for fasting blood glucose are presented in Supplementary Figure 8 and 9. There was significant effect modification by fructose-containing sugars dose ($\leq 10\%$ energy or $> 10\text{mmol/L}$) with a further threshold effect (25% energy) identified by the MKSPLINE procedure, comparator (starch, glucose, fat, mixed, lactose, dairy), baseline fasting blood glucose ($\leq 5.5\text{mmol/L}$ or $> 5.5\text{mmol/L}$), feeding control (dietary advice, supplementation, or metabolic), or underlying disease status (otherwise healthy, overweight/obese, diabetes, Metabolic syndrome, or NAFLD) in the substitution studies ($P < 0.05$). A significant subgroup effect was also observed by baseline fasting blood glucose ($\leq 5.5\text{mmol/L}$ or $> 5.5\text{mmol/L}$) in addition studies ($P=0.01$). None of the subgroup or dose-response analyses explained the substantial heterogeneity in the substitution and addition studies. No subgroup or dose-response analyses were conducted for subtraction or ad libitum comparisons as less than 10 studies were available for analyses.

Outcomes: Fasting Blood Insulin

The effect of different food sources of fructose-containing sugars on fasting blood insulin are shown in Figure 4 and Supplementary Figures 18-21. Total fructose-containing sugars independent of food sources had a harmful effect on fasting blood insulin in addition studies (23 study comparisons, MD=4.68 pmol/L [95% CI, 1.40 to 7.96], $p < 0.01$, substantial heterogeneity [$I^2=58\%$, $p < 0.001$]) and ad libitum studies (4 study comparisons, MD=7.24 pmol/L [95% CI, 0.47 to 14.00], $p=0.04$, no evidence of heterogeneity [$I^2=0\%$, $p=0.46$]). There was no effect in substitution (70 studies, substantial heterogeneity [$I^2=62\%$, $p < 0.001$]) or subtraction (3 studies, substantial heterogeneity [$I^2=79\%$, $p < 0.01$]) studies. There was a significant interaction by food source in substitution studies ($P < 0.001$): fruit juice (1 study

comparison, MD=-13.89 pmol/L [95%CI, -27.50 to -0.28], P=0.05) showed a beneficial effect; sweetened low-fat milk (2 study comparisons, MD=18.95 pmol/L [95%CI, 9.09 to 28.80], P<0.001, no evidence of heterogeneity) and mixed sources (25 study comparisons, MD=7.74 pmol/L [95%CI, 2.94 to 12.53], P<0.01, no substantial heterogeneity) showed a harmful effect; and fruit (6 study comparisons, no evidence of heterogeneity), dried fruit (1 study comparison), SSBs (17 study comparisons), baked goods, sweets, and desserts (10 study comparisons, no evidence of heterogeneity), and added sweeteners (8 study comparisons, substantial heterogeneity [I²=83, p<0.001]) showed no significant effect on fasting blood insulin. No significant interaction by food source was seen in the addition, ad libitum, or subtraction studies, although SSBs accounted for >50% of the weighted harm in addition studies and mixed sources was the exclusive food source of fructose-containing sugars in the ad libitum studies.

Sensitivity analyses for fasting blood insulin are presented in Supplementary table 3. Removal of the addition study by Hollis et al. 2009 (83) explained some of the heterogeneity (I²=42%, P=0.02), without changing the significance, magnitude, or direction of the effect. Removal of either one of two substitution studies (92, 104) changed the evidence of significance from non-significant to significant without changing the magnitude or direction of the effect or the evidence of substantial heterogeneity. Removal of the subtraction study by Campos et al. (G2) (60) explained nearly all of the heterogeneity (I²=1%, P=0.31) changing the significance and magnitude but not the direction of the effect. Removal of the ad libitum study by Raben et al. 2000 (C) (124) eliminated the evidence for the significance but not the direction of the effect or evidence of no substantial heterogeneity.

A priori subgroup analyses for fasting blood insulin are presented in supplementary figures 22-25 and dose-response analyses for fasting blood insulin are presented in Supplementary Figure 8 and 9. There was significant effect modification in substitution studies by level of feeding control (dietary advice, supplementation, or metabolic) or risk of bias for blinding of participants, personnel and outcome assessors (low, high, or unclear) in the substitution studies (P<0.05). None of the subgroup or dose-response analyses explained the substantial heterogeneity in the substitution studies. No subgroup or dose-response analyses were significant in the addition studies. No subgroup analyses were conducted for the subtraction or ad libitum studies, as less than 10 studies were available for analyses.

Publication Bias

The publication bias assessment is shown in Supplementary Figures 26 and 27 for all analyses where ≥10 studies were available. There was no evidence of publication bias for the effect of food sources of fructose containing sugars on HbA1c, fasting blood glucose, or fasting blood insulin. Although the Begg test was significant (P=0.04), visual inspection of funnel plots and the Egger test did not show evidence of publication bias for the effect of food sources of fructose containing sugars on fasting blood glucose in substitution studies. Adjustment for funnel plot asymmetry by the Duval and Tweedie method also did not alter the results.

GRADE Assessment

A summary of the overall quality of evidence assessment for the effect of total fructose-containing sugars independent of food source on the outcome measures of glycemic control is shown in Table 2. The certainty in the evidence was variable for HbA1c (low, low, low, and low), fasting blood glucose (low, low, moderate, and moderate) and fasting blood insulin (low, low, low, and moderate) across substitution, addition, subtraction, and ad libitum studies, respectively. Evidence for HbA1c was downgraded for inconsistency in substitution and addition studies, indirectness in subtraction and ad libitum studies, and for imprecision in substitution, addition, subtraction and ad libitum studies. Evidence for fasting blood glucose was downgraded for inconsistency in substitution and addition studies, and for imprecision in substitution, addition, subtraction and ad libitum studies. Similarly, evidence for fasting blood insulin was downgraded for inconsistency in the substitution, addition, and subtraction studies, and for imprecision in substitution, addition, subtraction and ad libitum studies.

DISCUSSION

Our systematic review and meta-analysis of 155 studies involving 5,086 participants with and without diabetes showed variable effects of food sources of fructose-containing sugars on three outcome measures of glycemic control at median doses ranging from 12.2-23% energy over median follow-up durations of 4.5-12 weeks. Four types of study designs were identified based on energy control. In substitution studies, total food sources of fructose-containing sugars in energy matched comparisons with other macronutrients (mainly refined starches) showed a beneficial effect on HbA1c with no effects on fasting blood glucose or insulin, while individual food sources showed decreasing (fruit juice), null (fruit, SSBs, baked goods, added sweeteners) or increasing (sweetened-milk, mixed sources) effects on fasting blood insulin. In addition studies, total food sources of fructose-containing sugars supplementing diets with excess energy compared to the same diet alone without the excess energy showed a harmful effect on fasting blood insulin without affecting HbA1c or fasting blood glucose, while individual food sources showed harmful effects on both fasting blood glucose (SSBs and fruit juice) and insulin (SSBs, mixed sources). In the ad libitum studies, total food sources of fructose-containing sugars freely replacing other macronutrients showed a harmful effect on fasting blood insulin (for which the effect was derived exclusively from mixed food sources inclusive of SSBs) without affecting HbA1c or fasting blood glucose. No effect of food sources of fructose-containing sugars was observed in subtraction studies.

Sources of heterogeneity

Methodological and clinical sources of heterogeneity had an influence on our results. Sensitivity analyses revealed evidence of instability in the significance of our pooled estimates. Removal of anyone of 6 studies (38, 46, 72, 105, 114, 123) changed the significance from non-significant to significant for fasting blood glucose in the addition studies, while the removal of a study by Raben et al. 2000 (C) (124) changed the significance from significant to non-significant for fasting blood insulin in the ad libitum studies. None of the studies explained any of the heterogeneity. Removal of the study by Campos et al. (G2) (60), however, did both explaining the heterogeneity and changing the significance of the effect. This sensitivity analysis revealed a consistent beneficial effect of reducing excess calories from fructose-containing sugars on fasting blood insulin in

subtraction studies. The reason for the strong influence of this study is unclear. As Campos et al. (G2) (60) was a small study (n=15) that received most of the weight in the analysis (>50%), it is possible that its true within-study variances were seriously underestimated, leading to an important outlier effect on the pooled estimate for fasting blood insulin (153).

Subgroup analyses also revealed evidence of effect modification under certain conditions. Greater improvements in fasting blood glucose were observed in participants with higher baseline fasting glucose in substitution and addition studies, suggesting a regression-to-the-mean phenomenon. These effects were concordant with the observed subgroup modification by underlying disease status in addition studies, demonstrating a greater beneficial effect on fasting blood glucose in patients with diabetes. Although a significant subgroup effect by level of feeding control and age were also observed in addition studies where fasting blood glucose was significantly reduced when dietary advice was the method of feeding control or the age of participants was ≤ 18 years, only one study was available for each of these analyses and neither analysis explained the substantial heterogeneity. The relevance of the subgroup analysis for feeding control is also brought into question by the finding of an opposite result for fasting blood insulin in substitution studies. The categorical subgroup analyses revealed a significant effect modification by dose, whereby fasting blood glucose was lower at doses of $\leq 10\%$ energy, suggesting that intakes that meet current recommendations to consume no more than 10% of energy from free or added sugars (22, 33) may have advantages. These results, however, are difficult to interpret in the absence of a linear dose response gradient or dose threshold effect in continuous analyses at this threshold or the other public health thresholds of 5% free sugars (22, 23) and 25% added sugars (34).

Results in the context of other studies

Our findings agree with two other previously conducted systematic reviews and meta-analyses of controlled intervention studies which demonstrated a beneficial effect of the isocaloric substitution of fructose for other carbohydrates on glycated blood proteins in participants with (equivalent to $\sim 0.53\%$ reduction in HbA1c)(13) and without (fructose intake < 90 g/d significantly improved HbA1c dependent on dose, study duration and severity of dysglycemia) diabetes (154). Although the modest decrease of -0.14% in HbA1c from our analysis did not exceed the clinically meaningful threshold of 0.3% proposed by the U.S Food and Drug administration for the development of new drugs for diabetes as observed in the previous meta-analysis (32), our findings suggest that food sources of fructose-containing sugars may have modest benefits for long term glycemic control when they replace other macronutrients on a calorie-for-calorie basis. On the other hand, our results suggest that food sources of fructose-containing sugars providing excess energy to the diet may raise fasting blood insulin agreeing with the findings from our previous systematic reviews and meta-analyses that fructose providing excess energy increases insulin resistance (155).

Our data also agree with evidence from prospective cohort studies of the relation of fructose-containing sugars with diabetes risk. While we failed to observe an adverse association of total fructose-containing sugars independent of food source with incident diabetes in an earlier systematic review and meta-analysis of the available prospective

cohort studies (156), differential associations have been shown for different food sources of sugars. Systematic reviews and meta-analyses of prospective cohort studies have shown an adverse association with SSBs (16, 17) but a protective association with fruit (18, 19), associations which are consistent with our findings of an harmful effect of SSBs on fasting blood glucose and insulin in addition studies and beneficial effect of fruit on HbA1c in substitution studies.

Potential mechanisms

Several proposed mechanisms may explain the observed beneficial effect of food sources of fructose-containing sugars on HbA1c when substituted for other calories in the diet. Fructose has a relatively low glycemic index (GI) of 16 compared to reference carbohydrates such as starch with a GI of 100 (157). As a majority of the comparators used in substitution studies were in the form of starch, replacement of these high-GI carbohydrates with fructose may have reduced the overall GI of the diet, leading to long term glycemic improvement (158) through alleviation of beta-cell stress (159, 160). There is also evidence that high-GI diets are associated with reliable clinical markers of insulin resistance such as higher triglycerides and lower HDL-C (161, 162). The low GI of fruit may explain why it was the main food source driving a significant improvement in HbA1c in substitution studies, especially when compared to intermediate GI food sources such as SSBs or sweets, which provide calories from sugars in the absence of any nutritional value. The higher fiber content of fruit may contribute to lower postprandial glycemic excursions. Particularly, viscous gels formed by the pectin in fruit may delay gastric emptying and slow down the release of sugars (163). A secondary analysis of a randomized controlled trial of the effect of a 6-month low-GI intervention showed that low-GI fruit intake was the strongest predictor of the reduction in HbA1c in people with type 2 diabetes (164). Whether or not low-GI food sources of fructose-containing sugars would show similar effects when compared to other low-GI carbohydrate foods, including legumes or some whole grains, remains to be determined as there is a lack of studies using high quality carbohydrate comparators. While a low-GI mechanism may have contributed to the observed decrease in HbA1c in the substitution studies), especially as it relates to fruit, it did not extend to improvements in fasting blood glucose and insulin. Although the summary effect estimates for both outcomes tended to be in the direction of benefit (with the possibility of additional studies providing sufficient power to confirm any beneficial effects), a mechanism that targets postprandial excursions in glucose and insulin would not necessarily be expected to lead to meaningful improvements in these fasting measurements which are more determined by changes in insulin sensitivity (158).

An alternative mechanism accounting for the observed beneficial effects of food sources of fructose-containing sugars on HbA1c in substitution studies relates to a so called “catalytic” effect of fructose whereby fructose metabolites have regulatory actions on glucokinase and hepatic glucose uptake. There is evidence that fructose, especially at small doses of $\leq 10\text{g}/\text{meal}$ (a level obtainable from fruit), may improve glycaemia by the ability of fructose-1-P to up regulate glucokinase activity through the glucokinase regulatory protein, resulting in decreased hepatic glucose production (165) and increased glycogen synthesis(166). The relevance of this mechanism is unclear. It has not been reliably shown (167, 168) under different experimental conditions and would be expected to have

disproportionally greater effect on fasting blood glucose and insulin than HbA1c, the opposite of what we found. How dietary fructose interacts with glucose at the level of hepatic glucose homeostasis remains largely under-explored.

The increase in insulin in the absence of a harmful effect on HbA1c or fasting blood glucose with sweetened low-fat milk in the substitution studies may relate to an isolated insulinotropic effect of dairy proteins. The ability of protein, especially dairy proteins, co-ingested with carbohydrate to stimulate glucose stimulated insulin secretion has been well described (169-171). This isolated finding does not necessarily imply harm, as fasting glucose was not increased and sweetened and unsweetened low-fat dairy, especially in the form of yogurt, is associated with decreased risk of weight gain and diabetes incidence (172).

In contrast, the observed harmful effects of food sources of fructose-containing sugars on glycemic control in addition studies appear to be largely driven by the energy contribution of the sugars. Fructose-containing sugars supplementing diets with excess calories may promote ectopic weight gain, contributing to downstream insulin resistance and impaired glycemic control. Related effects have been reported in systematic reviews and meta-analyses of controlled intervention studies of fructose overfeeding for body weight (173), blood pressure (174), uric acid levels (175), markers of Non-Alcoholic Fatty Liver Disease (NAFLD) (176) and postprandial triglycerides (177). Although fructose more than other carbohydrates (because of its ability to enter glycolysis as an unregulated substrate) has been proposed to increase de novo lipogenesis (DNL) leading to weight gain and its downstream cardiometabolic disturbances, this mechanism has been shown to be a minor pathway for fructose disposal (178). It is also not unique to fructose-containing sugars per se and weight gain with metabolic disturbances would be expected for the overconsumption of food sources of other dietary macronutrients (179).

The lack of a protective effect of interventions to reduce excess energy from food sources of fructose-containing sugars in subtraction studies is unclear. It may represent compensation, in which the decrease in energy from food sources of fructose-containing sugars are compensated by replacement with energy from other food sources or spontaneous changes in physical activity that decrease energy expenditure preventing weight loss and its downstream metabolic benefits. Compensation may have been more apparent in these studies as they had the longest median follow-up (12-weeks). It may explain why longer term (median follow-up, ~ 1 year) subtraction studies designed to displace excess energy from SSBs have only shown a weight-loss benefit in specific subgroups of overweight or obese individuals (180). The instability in the significance of the pooled effect estimates may have also played a role. Removal of the studies Campos et al. (G2) (60) explained the heterogeneity revealing significant beneficial effects on fasting insulin, suggesting that this study may have masked a true benefit of interventions to reduce fructose-containing sugars.

Implications

As dietary guidelines shift from a focus on individual nutrients towards a focus on foods and dietary patterns, our findings may have implications for guiding recommendations on important food sources of fructose-containing sugars in the prevention and management of diabetes. As various food sources of fructose-containing sugars tended to demonstrate

improvements in HbA1c, encouraging the consumption of food sources of sugars such as fruit, yogurt, and whole grain cereals to replace foods high in refined starches within the recommendation to consume no more than 10% of energy from free sugars (22, 32) may be an effective strategy for improving glycemic control, especially in people with diabetes. As SSBs tended to impair fasting blood glucose and insulin when adding excess energy to the diet, public health strategies to reduce consumption of this food source of fructose-containing sugars may be useful, especially as SSBs provide empty calories in absence of any nutritional “value”. While these findings highlight the role of food sources of fructose-containing sugars on glycemic control, other important cardiometabolic parameters should also be taken into consideration in future syntheses.

Strengths and Limitations

Our systematic review and meta-analysis has several strengths, including: 1) a comprehensive and reproducible search and selection process of the literature examining the effect of food sources of fructose-containing sugars on glycemic control, 2) collation and synthesis of the totality of the available evidence from a large body (155 studies, n=5,086) of controlled intervention studies which give the greatest protection against bias (noting that results did not differ between randomized and non-randomized studies), and 3) an assessment of overall quality of evidence using the GRADE assessment approach.

Several of our analyses presented limitations. First, despite the inclusion of a large number of studies, there was a limited number of studies using particular food sources. For example, there were no study comparisons available for sweetened breakfast cereals or yogurt and only one study comparison was available for sweetened chocolate and two study comparisons for sweetened low-fat milk for any of the analyses. Many analyses also had only one or two study comparisons available for inclusion: baked goods, sweets and desserts for HbA1c in substitution and addition studies (1 study); fruit juice for fasting blood glucose and insulin in substitution studies (1 study); mixed sources for fasting blood glucose and insulin in addition studies (1 study); SSBs for HbA1c in substitution studies (2 studies); and fruit juice for fasting blood glucose in addition studies (2 studies). As a result, we elected only to do GRADE assessments for total food sources. Second, substantial unexplained heterogeneity was present in all analyses for the substitution studies, as well as the addition studies for HbA1c, fasting blood glucose, and fasting blood insulin. Although there was also substantial heterogeneity present in the subtraction studies for HbA1c, fasting blood glucose and insulin, and ad libitum studies for HbA1c, the removal of individual studies during sensitivity analyses explained this heterogeneity, and so we did not downgrade for inconsistency. Third, serious indirectness was present in some analyses as only one trial in 240 overweight and obese women was available in the HbA1c subtraction analysis, and similarly, one trial in 10 patients with diabetes was available in the HbA1c ad libitum analysis. Although the small sample sizes of the included studies (median sample sizes ranged from 15 participants in subtraction studies to 39 participants in ad libitum studies) are another potential source of indirectness, we did not downgrade the evidence for indirectness owing to the very large number of included studies (155 study comparisons) representing a diverse range of study conditions and metabolic phenotypes across a large total number of participants (n=5,086). We also did not downgrade for indirectness based on the relatively short duration of follow-up (median follow-up, 4.5-12 weeks), as we felt that it was sufficient

to assess the question of harm (a decision shared with an earlier WHO commissioned review of the evidence for sugars and body weight (181)). Finally, there was evidence of serious imprecision in all of the analyses. As the 95% CIs crossed the MIDs for HbA1c, fasting blood glucose and fasting blood insulin, these analyses were downgraded for serious imprecision.

Weighing the strengths and limitations, we graded the certainty in the evidence using GRADE from low quality for HbA1c, low to moderate quality for fasting blood glucose and low to moderate quality for fasting blood insulin across the four study designs based on energy control.

CONCLUSION

In conclusion, the effects of food sources of fructose-containing sugars on glycemic control appear to be both energy and food source dependent. Food sources of fructose-containing sugars, especially fruit, substituted for equal amounts of calories from other macronutrient sources (mainly refined starches) led to improvements in HbA1c without adversely affecting fasting blood glucose or insulin. However, when several food sources of fructose-containing sugars added excess energy to the diet, especially SSBs, significant increases in fasting blood glucose and insulin were observed. The same was also seen for the effect of mixed food sources (inclusive of SSBs) of fructose-containing sugars freely replacing other macronutrients on fasting blood insulin without a harmful effect on HbA1c or fasting blood glucose. The anticipated benefit of interventions to reduce the excess energy from sugars, however, was not seen reliably, suggesting that compensatory behaviours may be an important consideration. The lack of any harm and even advantages were most pronounced in those with higher HbA1c and fasting blood glucose baseline levels or who had diabetes. While our findings may suggest that common food sources of fructose-containing sugars do not have harmful effects on glycemic control in energy matched replacement of other less sugary foods, our GRADE assessment suggests that more research is likely to have an important influence on many of our estimates. More large, high quality studies using a greater variety of food sources of fructose-containing sugars are required to assess the durability of these effects and understand whether certain food sources with an apparent signal for benefit, such as fruit, may even have advantages for glycemic control under free living conditions over the longer term (≥ 6 months). While awaiting these data, policy and guidelines makers should consider the influence of energy control and food source in the development recommendations to reduce sugars for the prevention and management of diabetes.

ACKNOWLEDGEMENTS

The authors thank Zujaja-Tul-Noor for her help in the creation of some figures. Aspects of this work were presented at the 34th International Symposium on Diabetes and Nutrition (ISDN), Diabetes and Nutrition Study Group (DNSG) of the European Association of the Study of Diabetes (EASD), Prague, Czech Republic, June 29-July 1, 2016.

CONTRIBUTIONS

VLC, SBM and JLS had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: VLC, JLS and DJAJ. Acquisition, analysis and interpretation of data: VLC, EV, SBM, AIC, VH, LAL, TMSW, TAK, DJAJ and JLS. Drafting of the manuscript: VLC. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: VLC and SBM. Study supervision: JLS and DJAJ. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

FUNDING STATEMENT

This work was funded by Diabetes Canada (grant # CS-5-15-4771-JS). The Diet, Digestive tract, and Disease (3-D) Centre, funded through the Canada Foundation for Innovation (CFI) and the Ministry of Research and Innovation's Ontario Research Fund (ORF), provided the infrastructure for the conduct of this work. David JA Jenkins was funded by the Government of Canada through the Canada Research Chair Endowment. John L Sievenpiper was funded by a PSI Graham Farquharson Knowledge Translation Fellowship, Diabetes Canada Clinician Scientist award, CIHR INMD/CNS New Investigator Partnership Prize, and Banting & Best Diabetes Centre Sun Life Financial New Investigator Award. None of the sponsors had a role in any aspect of the present study, including design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, approval of the manuscript or decision to publish.

COMPETING INTERESTS

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; Thomas M S Wolever is a part owner and the President of Glycemic Index Laboratories, Inc, Toronto, Canada, and has authored several popular diet books on the glycemic index for which he has received royalties from Phillipa Sandall Publishing Services and CABI Publishers. He has received consultant fees, honoraria, travel funding, or research support from or served on the scientific advisory board for CIHR, CDA, Dairy Farmers of Canada, McCain Foods, Temasek Polytechnic, Northwestern University, Royal Society of London, Glycemic Index Symbol program, CreaNutrition AG, McMaster University, Canadian Society for Nutritional Sciences, National Sports and Conditioning Association, Faculty of Public Health and Nutrition—Autonomous University of Nuevo Leon, Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Vladimir Vuksan has a Canadian (2,410,556) and American (7,326,404) patent on the medical use of viscous fiber blend for reducing blood glucose for treatment of diabetes, increasing insulin sensitivity, reduction in systolic blood pressure and blood lipids issued. Cyril WC Kendall has received research support from the Advanced Foods and Material Network, Agrifoods and Agriculture Canada, the Almond Board of California, the American Pistachio Growers, Barilla, the California Strawberry Commission, the Calorie Control Council, CIHR, the Canola Council of Canada, the Coca-Cola Company (investigator initiated, unrestricted grant), Hain Celestial, the International Tree Nut Council Nutrition Research and Education Foundation, Kellogg, Kraft, Loblaw Companies Ltd., Orafiti, Pulse Canada, Saskatchewan Pulse Growers, Solae and Unilever. He has received travel funding, consultant fees and/or honoraria from Abbott Laboratories, the Almond Board of California, the American Peanut Council, the American Pistachio Growers, Barilla, Bayer, the Canola

Council of Canada, the Coca-Cola Company, Danone, General Mills, the International Tree Nut Council Nutrition Research and Education Foundation, Kellogg, Loblaw Companies Ltd., the Nutrition Foundation of Italy, Oldways Preservation Trust, Orafti, Paramount Farms, the Peanut Institute, PepsiCo, Pulse Canada, Sabra Dipping Co., Saskatchewan Pulse Growers, Solae, Sun-Maid, Tate and Lyle, and Unilever. He is on the Dietary Guidelines Committee for the Diabetes Nutrition Study Group of the European Association for the Study of Diabetes and has served on the scientific advisory board for the Almond Board of California, the International Tree Nut Council, Oldways Preservation Trust, Paramount Farms and Pulse Canada. Russell J de Souza was previously funded by a CIHR Postdoctoral Fellowship Award and has received research support from the CIHR, the Calorie Control Council, the Canadian Foundation for Dietetic Research and the Coca-Cola Company (investigator initiated, unrestricted grant) and travel support from the World Health Organization (WHO) to attend group meetings. He has served as an external resource person to WHO's Nutrition Guidelines Advisory Group and is the lead author of 2 systematic reviews and meta-analyses commissioned by WHO of the relation of saturated fatty acids and trans fatty acids with health outcomes. David J.A. Jenkins has received research grants from Saskatchewan Pulse Growers, the Agricultural Bioproducts Innovation Program through the Pulse Research Network, the Advanced Foods and Material Network, Loblaw Companies Ltd., Unilever, Barilla, the Almond Board of California, Agriculture and Agri-food Canada, Pulse Canada, Kellogg's Company, Canada, Quaker Oats, Canada, Procter & Gamble Technical Centre Ltd., Bayer Consumer Care, Springfield, NJ, Pepsi/Quaker, International Nut & Dried Fruit (INC), Soy Foods Association of North America, the Coca-Cola Company (investigator initiated, unrestricted grant), Solae, Haine Celestial, the Sanitarium Company, Orafti, the International Tree Nut Council Nutrition Research and Education Foundation, the Peanut Institute, Soy Nutrition Institute (SNI), the Canola and Flax Councils of Canada, the Calorie Control Council (CCC), the CIHR, the Canada Foundation for Innovation and the Ontario Research Fund. He has received in-kind supplies for trials as a research support from the Almond board of California, Walnut Council of California, American Peanut Council, Barilla, Unilever, Unico, Primo, Loblaw Companies, Quaker (Pepsico), Pristine Gourmet, Bunge Limited, Kellogg Canada, WhiteWave Foods. He has been on the speaker's panel, served on the scientific advisory board and/or received travel support and/or honoraria from the Almond Board of California, Canadian Agriculture Policy Institute, Loblaw Companies Ltd, the Griffin Hospital (for the development of the NuVal scoring system, the Coca-Cola Company, EPICURE, Danone, Diet Quality Photo Navigation (DQPN), Better Therapeutics (FareWell), Verywell, True Health Initiative, Institute of Food Technologists (IFT), Soy Nutrition Institute (SNI), Herbalife Nutrition Institute (HNI), Saskatchewan Pulse Growers, Sanitarium Company, Orafti, the Almond Board of California, the American Peanut Council, the International Tree Nut Council Nutrition Research and Education Foundation, the Peanut Institute, Herbalife International, Pacific Health Laboratories, Nutritional Fundamentals for Health (NFH), Barilla, Metagenics, Bayer Consumer Care, Unilever Canada and Netherlands, Solae, Kellogg, Quaker Oats, Procter & Gamble, the Coca-Cola Company, the Griffin Hospital, Abbott Laboratories, the Canola Council of Canada, Dean Foods, the California Strawberry Commission, Haine Celestial, PepsiCo, the Alpro Foundation, Pioneer Hi-Bred International, DuPont Nutrition and Health, Spherix Consulting and WhiteWave Foods, the Advanced Foods and Material Network, the Canola and Flax Councils of Canada, the Nutritional Fundamentals for Health, Agri-Culture and Agri-Food Canada, the Canadian

Agri-Food Policy Institute, Pulse Canada, the Saskatchewan Pulse Growers, the Soy Foods Association of North America, the Nutrition Foundation of Italy (NFI), Nutra-Source Diagnostics, the McDougall Program, the Toronto Knowledge Translation Group (St. Michael's Hospital), the Canadian College of Naturopathic Medicine, The Hospital for Sick Children, the Canadian Nutrition Society (CNS), the American Society of Nutrition (ASN), Arizona State University, Paolo Sorbini Foundation and the Institute of Nutrition, Metabolism and Diabetes. He received an honorarium from the United States Department of Agriculture to present the 2013 W.O. Atwater Memorial Lecture. He received the 2013 Award for Excellence in Research from the International Nut and Dried Fruit Council. He received funding and travel support from the Canadian Society of Endocrinology and Metabolism to produce mini cases for the Canadian Diabetes Association (CDA). He is a member of the International Carbohydrate Quality Consortium (ICQC). His wife, ALJ, is a director and partner of Glycemic Index Laboratories, Inc., and his sister, CB, received funding through a grant from the St. Michael's Hospital Foundation to develop a cookbook for one of his studies.. John L Sievenpiper has received research support from the Canadian Institutes of health Research (CIHR), Canadian Diabetes Association (CDA), PSI Foundation, Calorie Control Council, Banting and Best Diabetes Centre (BBDC), American Society for Nutrition (ASN), Dr. Pepper Snapple Group (investigator initiated, unrestricted donation), INC International Nut and Dried Fruit Council, and The Tate and Lyle Nutritional Research Fund at the University of Toronto. He has received speaker fees and/or honoraria from the Canadian Diabetes Association (CDA), Canadian Nutrition Society (CNS), University of Alabama at Birmingham, Abbott Laboratories, Canadian Sugar Institute, Dr. Pepper Snapple Group, The Coca-Cola Company, Dairy Farmers of Canada, Nutrition Foundation of Italy (NFI), C3 Collaborating for Health, WhiteWave Foods, Rippe Lifestyle, mdBriefcase, Alberta Milk, FoodMinds LLC, Memac Ogilvy & Mather LLC, PepsiCo, and Pulse Canada. He has ad hoc consulting arrangements with Winston & Strawn LLP, Perkins Coie LLP, and Tate & Lyle. He is a member of the European Fruit Juice Association Scientific Expert Panel. He is on the Clinical Practice Guidelines Expert Committees of the Canadian Diabetes Association (CDA), European Association for the study of Diabetes (EASD), and Canadian Cardiovascular Society (CCS), as well as an expert writing panel of the American Society for Nutrition (ASN). He serves as an unpaid scientific advisor for the Food, Nutrition, and Safety Program (FNSP) and the Technical Committee on Carbohydrates of the International Life Science Institute (ILSI) North America. He is a member of the International Carbohydrate Quality Consortium (ICQC), Executive Board Member of the Diabetes and Nutrition Study Group (DNSG) of the EASD, and Director of the Toronto 3D Knowledge Synthesis and Clinical Studies foundation. His wife is an employee of Unilever Canada. No competing interests were declared by Vivian L Choo, Effie Vigiouk, Sonia Blanco Mejia, Adrian I Cozma, Tauseef A Khan, Vanessa Ha, and Lawrence A Leiter. There are no products in development or marketed products to declare.

EXCLUSIVE LICENCE

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide license (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the

Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution and convert or allow conversion into any format including without limitation audio, iii) create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) license any third party to do any or all of the above.

TRANSPARENCY DECLARATION

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

ETHICS APPROVAL

Not required.

DATA SHARING STATEMENT

No additional data are available.

References

1. Bray GA, Popkin BM. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: health be damned! Pour on the sugar. *Diabetes care*. 2014;37(4):950-6.
2. Kahn R, Sievenpiper JL. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: we have, but the pox on sugar is overwrought and overworked. *Diabetes care*. 2014;37(4):957-62.
3. Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. *The American journal of clinical nutrition*. 2004;79(5):774-9.
4. Goran MI, Ulijaszek SJ, Ventura EE. High fructose corn syrup and diabetes prevalence: a global perspective. *Global public health*. 2013;8(1):55-64.
5. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. *Jama*. 1986;256(23):3241-6.
6. Lustig RH. Fructose: it's "alcohol without the buzz". *Advances in nutrition*. 2013;4(2):226-35.
7. Huang BW, Chiang MT, Yao HT, Chiang W. The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. *Diabetes, obesity & metabolism*. 2004;6(2):120-6.
8. de Moura RF, Ribeiro C, de Oliveira JA, Stevanato E, de Mello MA. Metabolic syndrome signs in Wistar rats submitted to different high-fructose ingestion protocols. *The British journal of nutrition*. 2009;101(8):1178-84.
9. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. *Hypertension*. 1987;10(5):512-6.

10. Hendler R, Bonde AA. Effects of sucrose on resting metabolic rate, nitrogen balance, leucine turnover and oxidation during weight loss with low calorie diets. *International journal of obesity*. 1990;14(11):927-38.
11. Hendler RG, Walesky M, Sherwin RS. Sucrose substitution in prevention and reversal of the fall in metabolic rate accompanying hypocaloric diets. *The American journal of medicine*. 1986;81(2):280-4.
12. Yudkin J, Szanto S. Increased levels of plasma insulin and eleven hydroxycorticosteroid induced by sucrose, and their reduction by phenformin. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme*. 1972;4(6):417-20.
13. Cozma AI, Sievenpiper JL, de Souza RJ, Chiavaroli L, Ha V, Wang DD, et al. Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials. *Diabetes care*. 2012;35(7):1611-20.
14. White JS. Challenging the fructose hypothesis: new perspectives on fructose consumption and metabolism. *Advances in nutrition*. 2013;4(2):246-56.
15. Theytaz F, de Giorgi S, Hodson L, Stefanoni N, Rey V, Schneiter P, et al. Metabolic fate of fructose ingested with and without glucose in a mixed meal. *Nutrients*. 2014;6(7):2632-49.
16. Imamura F, O'Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. *BMJ*. 2015;351:h3576.
17. Greenwood DC, Threapleton DE, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, et al. Association between sugar-sweetened and artificially sweetened soft drinks and type 2 diabetes: systematic review and dose-response meta-analysis of prospective studies. *The British journal of nutrition*. 2014;112(5):725-34.
18. Li S, Miao S, Huang Y, Liu Z, Tian H, Yin X, et al. Fruit intake decreases risk of incident type 2 diabetes: an updated meta-analysis. *Endocrine*. 2015;48(2):454-60.
19. Muraki I, Imamura F, Manson JE, Hu FB, Willett WC, van Dam RM, et al. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. *BMJ*. 2013;347:f5001.
20. Manios Y, Moschonis G, Mavrogianni C, Tsoutsouloupoulou K, Kogkas S, Lambrinou CP, et al. Postprandial glucose and insulin levels in type 2 diabetes mellitus patients after consumption of ready-to-eat mixed meals. *European journal of nutrition*. 2017;56(3):1359-67.
21. Sievenpiper JL, Dworatzek PD. Food and dietary pattern-based recommendations: an emerging approach to clinical practice guidelines for nutrition therapy in diabetes. *Canadian journal of diabetes*. 2013;37(1):51-7.
22. Guideline: Sugars Intake for Adults and Children. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2015.
23. Scientific Advisory Committee on Nutrition. Carbohydrates and Health. The Stationery Office. Access date Nov 27 2017.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/445503/SACN_Carbohydrates_and_Health.pdf; 2015.

24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane collaboration Available from www.cochrane-handbook.org. 2011.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *International journal of surgery*. 2010;8(5):336-41.
26. Wilczynski NL, Morgan D, Haynes RB, Hedges T. An overview of the design and methods for retrieving high-quality studies for clinical care. *BMC medical informatics and decision making*. 2005;5:20.
27. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
28. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. *International journal of epidemiology*. 2002;31(1):140-9.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-60.
30. Borenstein M, Hedges LV, Higgins JP, H.R. R. Introduction to meta-analysis. Wiley J, editor 2008.
31. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med*. 2002;21(11):1559-73.
32. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015 – 2020 Dietary Guidelines for Americans. 8th Edition. December 2015. Available at <http://health.gov/dietaryguidelines/2015/guidelines/>.
33. USDA. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. In: DGAC-USDA, editor. 2015. <https://health.gov/dietaryguidelines/2015-scientific-report/pdfs/scientific-report-of-the-2015-dietary-guidelines-advisory-committee.pdf>.
34. Medicine Io. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press; 2005. 1358 p.
35. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol*. 2000;53(11):1119-29.
36. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56(2):455-63.
37. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-94.
38. Abdel-Sayed A, Binnert C, Le KA, Bortolotti M, Schneiter P, Tappy L. A high-fructose diet impairs basal and stress-mediated lipid metabolism in healthy male subjects. *The British journal of nutrition*. 2008;100(2):393-9.
39. Abdulrhman MM, El-Hefnawy MH, Aly RH, Shatla RH, Mamdouh RM, Mahmoud DM, et al. Metabolic effects of honey in type 1 diabetes mellitus: a randomized crossover pilot study. *Journal of medicinal food*. 2013;16(1):66-72.

40. Abaira C, Derler J. Large variations of sucrose in constant carbohydrate diets in type II diabetes. *The American journal of medicine*. 1988;84(2):193-200.
41. Aeberli I, Gerber PA, Hochuli M, Kohler S, Haile SR, Gouni-Berthold I, et al. Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial. *The American journal of clinical nutrition*. 2011;94(2):479-85.
42. Aeberli I, Hochuli M, Berneis K. Response to Comment on: Aeberli et al. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. *Diabetes Care* 2013;36:150-156. *Diabetes care*. 2013;36(7):e105.
43. Agebratt C, Strom E, Romu T, Dahlqvist-Leinhard O, Borga M, Leandersson P, et al. A Randomized Study of the Effects of Additional Fruit and Nuts Consumption on Hepatic Fat Content, Cardiovascular Risk Factors and Basal Metabolic Rate. *PLoS One*. 2016;11(1):e0147149.
44. Anderson JW, Story LJ, Zettwoch NC, Gustafson NJ, Jefferson BS. Metabolic effects of fructose supplementation in diabetic individuals. *Diabetes care*. 1989;12(5):337-44.
45. Anderson JW, Weiter KM, Christian AL, Ritchey MB, Bays HE. Raisins compared with other snack effects on glycemia and blood pressure: a randomized, controlled trial. *Postgraduate medicine*. 2014;126(1):37-43.
46. Bahrami M, Ataie-Jafari A, Hosseini S, Foruzanfar MH, Rahmani M, Pajouhi M. Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. *International journal of food sciences and nutrition*. 2009;60(7):618-26.
47. Banini AE, Boyd LC, Allen JC, Allen HG, Sauls DL. Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects. *Nutrition*. 2006;22(11-12):1137-45.
48. Bantle JP, Raatz SK, Thomas W, Georgopoulos A. Effects of dietary fructose on plasma lipids in healthy subjects. *The American journal of clinical nutrition*. 2000;72(5):1128-34.
49. Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary fructose in diabetic subjects. *Diabetes care*. 1992;15(11):1468-76.
50. Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary sucrose in type II diabetic subjects. *Diabetes care*. 1993;16(9):1301-5.
51. Basu A, Du M, Leyva MJ, Sanchez K, Betts NM, Wu M, et al. Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. *The Journal of nutrition*. 2010;140(9):1582-7.
52. Bays H, Weiter K, Anderson J. A randomized study of raisins versus alternative snacks on glycemic control and other cardiovascular risk factors in patients with type 2 diabetes mellitus. *The Physician and sportsmedicine*. 2015;43(1):37-43.
53. Beck-Nielsen H, Pedersen O, Lindskov HO. Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. *The American journal of clinical nutrition*. 1980;33(2):273-8.
54. Behall KM, Moser PB, Kelsay JL, Prather ES. The effect of kind of carbohydrate in the diet and use of oral contraceptives on metabolism of young women. III. Serum glucose, insulin, and glucagon. *The American journal of clinical nutrition*. 1980;33(5):1041-8.

55. Black RN, Spence M, McMahon RO, Cuskelly GJ, Ennis CN, McCance DR, et al. Effect of eucaloric high- and low-sucrose diets with identical macronutrient profile on insulin resistance and vascular risk: a randomized controlled trial. *Diabetes*. 2006;55(12):3566-72.
56. Blayo A, Fontevieille S, Rizkalla S, Bruzzo F, Slama G. Effets métaboliques de la consommation quotidienne pendant un an de saccharose ou de fructose par des diabétiques. *Médecine et Nutrition*. 1990;26(1):11-4.
57. Brymora A, Flisinski M, Johnson RJ, Goszka G, Stefanska A, Manitius J. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2012;27(2):608-12.
58. Brynes AE, Mark Edwards C, Ghatei MA, Dornhorst A, Morgan LM, Bloom SR, et al. A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men. *The British journal of nutrition*. 2003;89(2):207-18.
59. Buysschaert M, Sory R, Mpoy M, Lambert AE. Effect of the addition of simple sugars to mixed meals on the glycemic control of insulin treated diabetic patients. *Diabete & métabolisme*. 1987;13(6):625-9.
60. Campos V, Despland C, Brandejsky V, Kreis R, Schneiter P, Chiolero A, et al. Sugar- and artificially sweetened beverages and intrahepatic fat: A randomized controlled trial. *Obesity*. 2015;23(12):2335-9.
61. Chantelau EA, Gosseringer G, Sonnenberg GE, Berger M. Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. *Diabetologia*. 1985;28(4):204-7.
62. Christensen AS, Viggers L, Hasselstrom K, Gregersen S. Effect of fruit restriction on glycemic control in patients with type 2 diabetes--a randomized trial. *Nutrition journal*. 2013;12:29.
63. Claesson AL, Holm G, Ernerson A, Lindstrom T, Nystrom FH. Two weeks of overfeeding with candy, but not peanuts, increases insulin levels and body weight. *Scandinavian journal of clinical and laboratory investigation*. 2009;69(5):598-605.
64. Colagiuri S, Miller JJ, Edwards RA. Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. *The American journal of clinical nutrition*. 1989;50(3):474-8.
65. Conceicao de Oliveira M, Sichieri R, Sanchez Moura A. Weight loss associated with a daily intake of three apples or three pears among overweight women. *Nutrition*. 2003;19(3):253-6.
66. Cooper PL, Wahlqvist ML, Simpson RW. Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. *Diabetic medicine : a journal of the British Diabetic Association*. 1988;5(7):676-80.
67. Costa PC, Franco LJ. [Introduction of sucrose in the diet plan of persons with type 1 diabetes: its influence in the glycemic control]. *Arquivos brasileiros de endocrinologia e metabologia*. 2005;49(3):403-9.
68. Coulston AM, Hollenbeck CB, Donner CC, Williams R, Chiou YA, Reaven GM. Metabolic effects of added dietary sucrose in individuals with noninsulin-dependent diabetes mellitus (NIDDM). *Metabolism*. 1985;34(10):962-6.
69. Cressey R, Kumsaiyai W, Mangklabruks A. Daily consumption of banana marginally improves blood glucose and lipid profile in hypercholesterolemic subjects and increases

serum adiponectin in type 2 diabetic patients. *Indian journal of experimental biology*. 2014;52(12):1173-81.

70. Despland C, Walther B, Kast C, Campos V, Rey V, Stefanoni N, et al. A randomized-controlled clinical trial of high fructose diets from either Robinia honey or free fructose and glucose in healthy normal weight males. *Clinical Nutrition ESPEN*. 2017;19:16-22.
71. Dunnigan MG, Fyfe T, McKiddie MT, Crosbie SM. The effects of isocaloric exchange of dietary starch and sucrose on glucose tolerance, plasma insulin and serum lipids in man. *Clinical science*. 1970;38(1):1-9.
72. Ellis CL, Edirisinghe I, Kappagoda T, Burton-Freeman B. Attenuation of meal-induced inflammatory and thrombotic responses in overweight men and women after 6-week daily strawberry (*Fragaria*) intake. A randomized placebo-controlled trial. *Journal of atherosclerosis and thrombosis*. 2011;18(4):318-27.
73. Emanuele MA, Abaira C, Jellish WS, DeBartolo M. A crossover trial of high and low sucrose-carbohydrate diets in type II diabetics with hypertriglyceridemia. *Journal of the American College of Nutrition*. 1986;5(5):429-37.
74. Enginyurt O, Cakir L, Karatas A, Cankaya S, Kaya Y, Handan Tugcu H, et al. The role of pure honey in the treatment of diabetes mellitus. *Biomedical Research (India)*. 2017;28(7):3305-12.
75. Friedman M, Rosenman RH, Byers SO, Elevitch FR. Effect of low sugar intake upon blood lipids and insulin levels of hyperlipemic subjects. *Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine*. 1970;135(3):785-91.
76. Fry AJ. The effect of a 'sucrose-free' diet on oral glucose tolerance in man. *Nutrition and metabolism*. 1972;14(5):313-23.
77. Grigoresco C, Rizkalla SW, Halfon P, Bornet F, Fontvieille AM, Bros M, et al. Lack of detectable deleterious effects on metabolic control of daily fructose ingestion for 2 mo in NIDDM patients. *Diabetes care*. 1988;11(7):546-50.
78. Hallfrisch J, Ellwood KC, Michaelis OEt, Reiser S, O'Dorisio TM, Prather ES. Effects of dietary fructose on plasma glucose and hormone responses in normal and hyperinsulinemic men. *The Journal of nutrition*. 1983;113(9):1819-26.
79. Heden TD, Liu Y, Park YM, Nyhoff LM, Winn NC, Kanaley JA. Moderate amounts of fructose- or glucose-sweetened beverages do not differentially alter metabolic health in male and female adolescents. *The American journal of clinical nutrition*. 2014;100(3):796-805.
80. Heden TD, Liu Y, Park YM, Winn NC, Kanaley JA. Walking Reduces Postprandial Insulin Secretion in Obese Adolescents Consuming a High-Fructose or High-Glucose Diet. *Journal of physical activity & health*. 2015;12(8):1153-61.
81. Hegde SV, Adhikari P, M N, D'Souza V. Effect of daily supplementation of fruits on oxidative stress indices and glycaemic status in type 2 diabetes mellitus. *Complementary therapies in clinical practice*. 2013;19(2):97-100.
82. Hernandez-Cordero S, Barquera S, Rodriguez-Ramirez S, Villanueva-Borbolla MA, Gonzalez de Cossio T, Dommarco JR, et al. Substituting water for sugar-sweetened beverages reduces circulating triglycerides and the prevalence of metabolic syndrome in obese but not in overweight Mexican women in a randomized controlled trial. *The Journal of nutrition*. 2014;144(11):1742-52.

83. Hollis JH, Houchins JA, Blumberg JB, Mattes RD. Effects of concord grape juice on appetite, diet, body weight, lipid profile, and antioxidant status of adults. *Journal of the American College of Nutrition*. 2009;28(5):574-82.
84. Huttunen JK, Makinen KK, Scheinin A. Turku sugar studies XI. Effects of sucrose, fructose and xylitol diets on glucose, lipid and urate metabolism. *Acta odontologica Scandinavica*. 1976;34(6):345-51.
85. Jellish WS, Emanuele MA, Abraira C. Graded sucrose/carbohydrate diets in overtly hypertriglyceridemic diabetic patients. *The American journal of medicine*. 1984;77(6):1015-22.
86. Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. *Nutrients*. 2014;6(8):3187-201.
87. Jones JB, Provost M, Keaver L, Breen C, Ludy MJ, Mattes RD. A randomized trial on the effects of flavorings on the health benefits of daily peanut consumption. *The American journal of clinical nutrition*. 2014;99(3):490-6.
88. Johnston RD, Stephenson MC, Crossland H, Cordon SM, Palcidi E, Cox EF, et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. *Gastroenterology*. 2013;145(5):1016-25 e2.
89. Kaliora AC, Kokkinos A, Diolintzi A, Stoupaki M, Gioxari A, Kanellos PT, et al. The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention. *Food Funct*. 2016;7(11):4533-44.
90. Kanellos PT, Kaliora AC, Tentolouris NK, Argiana V, Perrea D, Kalogeropoulos N, et al. A pilot, randomized controlled trial to examine the health outcomes of raisin consumption in patients with diabetes. *Nutrition*. 2014;30(3):358-64.
91. Kelsay JL, Behall KM, Holden JM, Prather ES. Diets high in glucose or sucrose and young women. *The American journal of clinical nutrition*. 1974;27(9):926-36.
92. Koh ET, Ard NF, Mendoza F. Effects of fructose feeding on blood parameters and blood pressure in impaired glucose-tolerant subjects. *Journal of the American Dietetic Association*. 1988;88(8):932-8.
93. Koivisto VA, Yki-Jarvinen H. Fructose and insulin sensitivity in patients with type 2 diabetes. *Journal of internal medicine*. 1993;233(2):145-53.
94. Kolehmainen M, Mykkanen O, Kirjavainen PV, Leppanen T, Moilanen E, Adriaens M, et al. Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome. *Molecular nutrition & food research*. 2012;56(10):1501-10.
95. Koopman KE, Caan MW, Nederveen AJ, Pels A, Ackermans MT, Fliers E, et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. *Hepatology*. 2014;60(2):545-53.
96. Le KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, et al. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. *The American journal of clinical nutrition*. 2006;84(6):1374-9.
97. Le KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. *The American journal of clinical nutrition*. 2009;89(6):1760-5.
98. Lehtonen HM, Suomela JP, Tahvonen R, Vaarno J, Venojarvi M, Viikari J, et al. Berry meals and risk factors associated with metabolic syndrome. *European journal of clinical nutrition*. 2010;64(6):614-21.

99. Lewis AS, McCourt HJ, Ennis CN, Bell PM, Courtney CH, McKinley MC, et al. Comparison of 5% versus 15% sucrose intakes as part of a eucaloric diet in overweight and obese subjects: effects on insulin sensitivity, glucose metabolism, vascular compliance, body composition and lipid profile. A randomised controlled trial. *Metabolism*. 2013;62(5):694-702.
100. Liu G, Coulston A, Hollenbeck C, Reaven G. The effect of sucrose content in high and low carbohydrate diets on plasma glucose, insulin, and lipid responses in hypertriglyceridemic humans. *The Journal of clinical endocrinology and metabolism*. 1984;59(4):636-42.
101. Lock S, Ford MA, Bagley R, Green LF. The effect on plasma lipids of the isoenergetic replacement of table sucrose by dried glucose syrup (maize-syrup solids) in the normal diet of adult men over a period of 1 year. *The British journal of nutrition*. 1980;43(2):251-6.
102. Lowndes J, Sinnott SS, Rippe JM. No Effect of Added Sugar Consumed at Median American Intake Level on Glucose Tolerance or Insulin Resistance. *Nutrients*. 2015;7(10):8830-45.
103. Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Perez-Mendez O, et al. The effect of two energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and metabolic syndrome parameters: a randomized controlled trial. *Metabolism*. 2011;60(11):1551-9.
104. Maersk M, Belza A, Stodkilde-Jorgensen H, Ringgaard S, Chabanova E, Thomsen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. *The American journal of clinical nutrition*. 2012;95(2):283-9.
105. Majid M, Younis MA, Naveed AK, Shah MU, Azeem Z, Tirmizi SH. Effects of natural honey on blood glucose and lipid profile in young healthy Pakistani males. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2013;25(3-4):44-7.
106. Maki KC, Nieman KM, Schild AL, Kaden VN, Lawless AL, Kelley KM, et al. Sugar-sweetened product consumption alters glucose homeostasis compared with dairy product consumption in men and women at risk of type 2 diabetes mellitus. *The Journal of nutrition*. 2015;145(3):459-66.
107. Malerbi DA, Paiva ES, Duarte AL, Wajchenberg BL. Metabolic effects of dietary sucrose and fructose in type II diabetic subjects. *Diabetes care*. 1996;19(11):1249-56.
108. Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. *Diabetes care*. 2014;37(1):88-95.
109. Markey O, Le Jeune J, Lovegrove JA. Energy compensation following consumption of sugar-reduced products: a randomized controlled trial. *European journal of nutrition*. 2015.
110. McAteer EJ, O'Reilly G, Hadden DR. The effects of one month high fructose intake on plasma glucose and lipid levels in non-insulin-dependent diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 1987;4(1):62-4.
111. Mitsou EK, Kougia E, Nomikos T, Yannakoulia M, Mountzouris KC, Kyriacou A. Effect of banana consumption on faecal microbiota: a randomised, controlled trial. *Anaerobe*. 2011;17(6):384-7.
112. Moazen S, Amani R, Homayouni Rad A, Shahbazian H, Ahmadi K, Taha Jalali M. Effects of freeze-dried strawberry supplementation on metabolic biomarkers of atherosclerosis in subjects with type 2 diabetes: a randomized double-blind controlled trial. *Annals of nutrition & metabolism*. 2013;63(3):256-64.

113. Ngo Sock ET, Le KA, Ith M, Kreis R, Boesch C, Tappy L. Effects of a short-term overfeeding with fructose or glucose in healthy young males. *The British journal of nutrition*. 2010;103(7):939-43.
114. Njike VY, Faridi Z, Shuval K, Dutta S, Kay CD, West SG, et al. Effects of sugar-sweetened and sugar-free cocoa on endothelial function in overweight adults. *International journal of cardiology*. 2011;149(1):83-8.
115. Osei K, Bossetti B. Dietary fructose as a natural sweetener in poorly controlled type 2 diabetes: a 12-month crossover study of effects on glucose, lipoprotein and apolipoprotein metabolism. *Diabetic medicine : a journal of the British Diabetic Association*. 1989;6(6):506-11.
116. Osei K, Falko J, Bossetti BM, Holland GC. Metabolic effects of fructose as a natural sweetener in the physiologic meals of ambulatory obese patients with type II diabetes. *The American journal of medicine*. 1987;83(2):249-55.
117. Paganus A, Maenpaa J, Akerblom HK, Stenman UH, Knip M, Simell O. Beneficial effects of palatable guar and guar plus fructose diets in diabetic children. *Acta paediatrica Scandinavica*. 1987;76(1):76-81.
118. Paineau DL, Beaufile F, Boulier A, Cassuto DA, Chwalow J, Combris P, et al. Family dietary coaching to improve nutritional intakes and body weight control: a randomized controlled trial. *Archives of pediatrics & adolescent medicine*. 2008;162(1):34-43.
119. Pelkonen R, Aro A, Nikkila EA. Metabolic effects of dietary fructose in insulin dependent diabetes of adults. *Acta medica Scandinavica Supplementum*. 1972;542:187-93.
120. Peterson DB, Lambert J, Gerring S, Darling P, Carter RD, Jelfs R, et al. Sucrose in the diet of diabetic patients--just another carbohydrate? *Diabetologia*. 1986;29(4):216-20.
121. Poppitt SD, Keogh GF, Prentice AM, Williams DE, Sonnemans HM, Valk EE, et al. Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. *The American journal of clinical nutrition*. 2002;75(1):11-20.
122. Porta M, Pigino M, Minonne A, Morisio Guidetti L. Moderate Amounts of Sucrose with Mixed Meals do not Impair Metabolic Control in Patients with Type II (Non-Insulin Dependent) Diabetes. *Diabetes, Nutrition & Metabolism*. 1989;2(2):133-7.
123. Puglisi MJ, Vaishnav U, Shrestha S, Torres-Gonzalez M, Wood RJ, Volek JS, et al. Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. *Lipids in health and disease*. 2008;7:14.
124. Raben A, Astrup A. Leptin is influenced both by predisposition to obesity and diet composition. *International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity*. 2000;24(4):450-9.
125. Raben A, Moller BK, Flint A, Vasilaris TH, Christina Moller A, Juul Holst J, et al. Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks' sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial. *Food & nutrition research*. 2011;55.
126. Rath R, Masek J, Kujalova V, Slabochova Z. Effect of a high sugar intake on some metabolic and regulatory indicators in young men. *Die Nahrung*. 1974;18(4):343-53.
127. Ravn-Haren G, Dragsted LO, Buch-Andersen T, Jensen EN, Jensen RI, Nemeth-Balogh M, et al. Intake of whole apples or clear apple juice has contrasting effects on plasma lipids in healthy volunteers. *European journal of nutrition*. 2013;52(8):1875-89.

128. Reiser S, Hallfrisch J, Fields M, Powell A, Mertz W, Prather ES, et al. Effects of sugars on indices of glucose tolerance in humans. *The American journal of clinical nutrition*. 1986;43(1):151-9.
129. Reiser S, Powell AS, Scholfield DJ, Panda P, Fields M, Canary JJ. Day-long glucose, insulin, and fructose responses of hyperinsulinemic and nonhyperinsulinemic men adapted to diets containing either fructose or high-amylose cornstarch. *The American journal of clinical nutrition*. 1989;50(5):1008-14.
130. Ribeiro C, Dourado G, Cesar T. Orange juice allied to a reduced-calorie diet results in weight loss and ameliorates obesity-related biomarkers: A randomized controlled trial. *Nutrition*. 2017;38:13-9.
131. Rodriguez MC, Parra MD, Marques-Lopes I, De Morentin BE, Gonzalez A, Martinez JA. Effects of two energy-restricted diets containing different fruit amounts on body weight loss and macronutrient oxidation. *Plant foods for human nutrition*. 2005;60(4):219-24.
132. Santacroce G, Forlani G, Giangiulio S, Galuppi V, Pagani M, Vannini P. Long-term effects of eating sucrose on metabolic control of type 1 (insulin-dependent) diabetic outpatients. *Acta diabetologica latina*. 1990;27(4):365-70.
133. Saris WH, Astrup A, Prentice AM, Zunft HJ, Formiguera X, Verboeket-van de Venne WP, et al. Randomized controlled trial of changes in dietary carbohydrate/fat ratio and simple vs complex carbohydrates on body weight and blood lipids: the CARMEN study. *The Carbohydrate Ratio Management in European National diets. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity*. 2000;24(10):1310-8.
134. Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, et al. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. *The Journal of clinical endocrinology and metabolism*. 2015;100(6):2434-42.
135. Schwingshandl J, Rippel S, Unterluggauer M, Borkenstein M. Effect of the introduction of dietary sucrose on metabolic control in children and adolescents with type I diabetes. *Acta diabetologica*. 1994;31(4):205-9.
136. Silbernagel G, Machann J, Unmuth S, Schick F, Stefan N, Haring HU, et al. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. *The British journal of nutrition*. 2011;106(1):79-86.
137. Singh RB, Rastogi SS, Singh R, Niaz MA, Singh NK, Madhu SV. Effects on Plasma Ascorbic Acid and Coronary Risk Factors of Adding Guava Fruit to the Usual Diet in Hypertensives with Mild to Moderate Hypercholesterolaemia. *Journal of Nutritional & Environmental Medicine*. 1997;7:5-14.
138. Sobrecases H, Le KA, Bortolotti M, Schneiter P, Ith M, Kreis R, et al. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. *Diabetes & metabolism*. 2010;36(3):244-6.
139. Souto DL, Zajdenverg L, Rodacki M, Rosado EL. Does sucrose intake affect antropometric variables, glycemia, lipemia and C-reactive protein in subjects with type 1 diabetes?: a controlled-trial. *Diabetology & metabolic syndrome*. 2013;5(1):67.
140. Stanhope KL, Griffen SC, Bremer AA, Vink RG, Schaefer EJ, Nakajima K, et al. Metabolic responses to prolonged consumption of glucose- and fructose-sweetened beverages are not associated with postprandial or 24-h glucose and insulin excursions. *The American journal of clinical nutrition*. 2011;94(1):112-9.

141. Stanhope KL, Bremer AA, Medici V, Nakajima K, Ito Y, Nakano T, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. *The Journal of clinical endocrinology and metabolism*. 2011;96(10):E1596-605.
142. Sunehag AL, Toffolo G, Campioni M, Bier DM, Haymond MW. Short-term high dietary fructose intake had no effects on insulin sensitivity and secretion or glucose and lipid metabolism in healthy, obese adolescents. *Journal of pediatric endocrinology & metabolism : JPEM*. 2008;21(3):225-35.
143. Sunehag AL, Toffolo G, Treuth MS, Butte NF, Cobelli C, Bier DM, et al. Effects of dietary macronutrient content on glucose metabolism in children. *The Journal of clinical endocrinology and metabolism*. 2002;87(11):5168-78.
144. Surwit RS, Feinglos MN, McCaskill CC, Clay SL, Babyak MA, Brownlow BS, et al. Metabolic and behavioral effects of a high-sucrose diet during weight loss. *The American journal of clinical nutrition*. 1997;65(4):908-15.
145. Swanson JE, Laine DC, Thomas W, Bantle JP. Metabolic effects of dietary fructose in healthy subjects. *The American journal of clinical nutrition*. 1992;55(4):851-6.
146. Swarbrick MM, Stanhope KL, Elliott SS, Graham JL, Krauss RM, Christiansen MP, et al. Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein-B concentrations in overweight and obese women. *The British journal of nutrition*. 2008;100(5):947-52.
147. Szanto S, Yudkin J. The effect of dietary sucrose on blood lipids, serum insulin, platelet adhesiveness and body weight in human volunteers. *Postgraduate medical journal*. 1969;45(527):602-7.
148. Tate DF, Turner-McGrievy G, Lyons E, Stevens J, Erickson K, Polzien K, et al. Replacing caloric beverages with water or diet beverages for weight loss in adults: main results of the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial. *The American journal of clinical nutrition*. 2012;95(3):555-63.
149. Vaisman N, Niv E, Izkhakov Y. Catalytic amounts of fructose may improve glucose tolerance in subjects with uncontrolled non-insulin-dependent diabetes. *Clinical nutrition*. 2006;25(4):617-21.
150. van Meijl LE, Mensink RP. Low-fat dairy consumption reduces systolic blood pressure, but does not improve other metabolic risk parameters in overweight and obese subjects. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2011;21(5):355-61.
151. Volp AC, Hermsdorff HH, Bressan J. Glycemia and insulinemia evaluation after high-sucrose and high-fat diets in lean and overweight/obese women. *Journal of physiology and biochemistry*. 2008;64(2):103-13.
152. Volp AC, Hermsdorff HM, Bressan J. [Effect of high sucrose- and high-fat diets ingested under free-living conditions in insulin resistance in normal weight and overweight women]. *Nutricion hospitalaria*. 2007;22(1):46-60.
153. Lin L, Chu H, Hodges JS. Alternative measures of between-study heterogeneity in meta-analysis: Reducing the impact of outlying studies. *Biometrics*. 2017;73(1):156-66.
154. Livesey G, Taylor R. Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies. *The American journal of clinical nutrition*. 2008;88(5):1419-37.
155. Sievenpiper JL. Sickeningly Sweet: Does Sugar Cause Chronic Disease? No. *Canadian journal of diabetes*. 2016;40(4):287-95.

156. Tsilas CS, de Souza RJ, Mejia SB, Mirrahimi A, Cozma AI, Jayalath VH, et al. Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2017;189(20):E711-E20.
157. Atkinson FS, Foster-Powell K, Brand-Miller JC. International tables of glycemic index and glycemic load values: 2008. *Diabetes care*. 2008;31(12):2281-3.
158. Livesey G, Taylor R, Hulshof T, Howlett J. Glycemic response and health--a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. *The American journal of clinical nutrition*. 2008;87(1):258S-68S.
159. Brand-Miller JC, Petocz P, Colagiuri S. Meta-analysis of low-glycemic index diets in the management of diabetes: response to Franz. *Diabetes care*. 2003;26(12):3363-4; author reply 4-5.
160. Jenkins DJ, Wolever TM, Collier GR, Ocana A, Rao AV, Buckley G, et al. Metabolic effects of a low-glycemic-index diet. *The American journal of clinical nutrition*. 1987;46(6):968-75.
161. Ford ES, Liu S. Glycemic index and serum high-density lipoprotein cholesterol concentration among us adults. *Arch Intern Med*. 2001;161(4):572-6.
162. Liu S, Manson JE, Stampfer MJ, Holmes MD, Hu FB, Hankinson SE, et al. Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. *The American journal of clinical nutrition*. 2001;73(3):560-6.
163. Lattimer JM, Haub MD. Effects of dietary fiber and its components on metabolic health. *Nutrients*. 2010;2(12):1266-89.
164. Jenkins DJ, Srichaikul K, Kendall CW, Sievenpiper JL, Abdulnour S, Mirrahimi A, et al. The relation of low glycaemic index fruit consumption to glycaemic control and risk factors for coronary heart disease in type 2 diabetes. *Diabetologia*. 2011;54(2):271-9.
165. Hawkins M, Gabriely I, Wozniak R, Vilcu C, Shamooh H, Rossetti L. Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes. *Diabetes*. 2002;51(3):606-14.
166. Petersen KF, Laurent D, Yu C, Cline GW, Shulman GI. Stimulating effects of low-dose fructose on insulin-stimulated hepatic glycogen synthesis in humans. *Diabetes*. 2001;50(6):1263-8.
167. Braunstein CR, Noronha JC, Glenn AJ, Viguiliouk E, Noseworthy R, Khan TA, et al. A Double-Blind, Randomized Controlled, Acute Feeding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Blood Glucose Metabolism in Healthy Participants: The Fructose and Allulose Catalytic Effects (FACE) Trial. *Nutrients*. 2018;10(6).
168. Noronha JC, Braunstein CR, Glenn AJ, Khan TA, Viguiliouk E, Noseworthy R, et al. The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial. *Diabetes, obesity & metabolism*. 2018.
169. Lan-Pidhainy X, Wolever TM. The hypoglycemic effect of fat and protein is not attenuated by insulin resistance. *The American journal of clinical nutrition*. 2010;91(1):98-105.
170. Wolever TM, van Klinken BJ, Bordenave N, Kaczmarczyk M, Jenkins AL, Chu Y, et al. Reformulating cereal bars: high resistant starch reduces in vitro digestibility but not in vivo

glucose or insulin response; whey protein reduces glucose but disproportionately increases insulin. *The American journal of clinical nutrition*. 2016;104(4):995-1003.

171. Jakubowicz D, Froy O, Ahren B, Boaz M, Landau Z, Bar-Dayana Y, et al. Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. *Diabetologia*. 2014;57(9):1807-11.

172. Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. *Circulation*. 2016;133(2):187-225.

173. Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, et al. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. *Annals of internal medicine*. 2012;156(4):291-304.

174. Silbernagel G, Kovarova M, Cegan A, Machann J, Schick F, Lehmann R, et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. *The Journal of clinical endocrinology and metabolism*. 2012;97(12):E2288-92.

175. Wang DD, Sievenpiper JL, de Souza RJ, Chiavaroli L, Ha V, Cozma AI, et al. The effects of fructose intake on serum uric acid vary among controlled dietary trials. *The Journal of nutrition*. 2012;142(5):916-23.

176. Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. *European journal of clinical nutrition*. 2014;68(4):416-23.

177. David Wang D, Sievenpiper JL, de Souza RJ, Cozma AI, Chiavaroli L, Ha V, et al. Effect of fructose on postprandial triglycerides: a systematic review and meta-analysis of controlled feeding trials. *Atherosclerosis*. 2014;232(1):125-33.

178. van Buul VJ, Tappy L, Brouns FJ. Misconceptions about fructose-containing sugars and their role in the obesity epidemic. *Nutrition research reviews*. 2014;27(1):119-30.

179. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. *The New England journal of medicine*. 2011;364(25):2392-404.

180. Kaiser KA, Shikany JM, Keating KD, Allison DB. Will reducing sugar-sweetened beverage consumption reduce obesity? Evidence supporting conjecture is strong, but evidence when testing effect is weak. *Obesity reviews : an official journal of the International Association for the Study of Obesity*. 2013;14(8):620-33.

181. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. *BMJ*. 2012;346:e7492.

Figures and Tables

Figure 1. Flow of literature for the effect of food sources of fructose-containing sugars on glycemic control.

Figure 2. Summary super-plot for the effect of food sources of fructose-containing sugars on HbA1c. N= Number of participants. Data are expressed as weighted mean differences (MD) with 95% CIs for summary effects of individual food sources and total on HbA1c. Analyses were conducted using generic inverse variance random-effects models (≥ 5 trials available) or fixed effects models (<5 trials available). Interstudy heterogeneity was tested using the Cochran's Q statistic (chi-square) at a significance level of $P < 0.10$.

Figure 3. Summary super-plot for the effect of food sources of fructose-containing sugars on fasting blood glucose. N= Number of participants. Data are expressed as weighted mean

differences (MD) with 95% CIs for summary effects of individual food sources and total on fasting blood glucose. Analyses were conducted using generic inverse variance random-effects models (≥ 5 trials available) or fixed effects models (<5 trials available). Interstudy heterogeneity was tested using the Cochran's Q statistic (chi-square) at a significance level of $P < 0.10$.

Figure 4. Summary super-plot for the effect of food sources of fructose-containing sugars on fasting blood insulin. N= Number of participants. Data are expressed as weighted mean differences (MD) with 95% CIs for summary effects of individual food sources and total on fasting blood insulin. Analyses were conducted using generic inverse variance random-effects models (≥ 5 trials available) or fixed effects models (<5 trials available). Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of $P < 0.10$.